Policy and practice for maturity-aligned engagement of children in decisions about HIV-related medical and social services and management of confidential information
Kipling Beardsley, Health Policy Plus
Accessed: 26.10.2019
Case Study on Improving HIV Testing and Services for Children Orphaned or made Vulnerable by HIV (OVC)
Expanded IMPACT Program in Zimbabwe
Lea Toto and APHIAplus Nuru ya Bonde programs in Kenya Yekokeb Berhan Program for Highly Vulnerable Children in Ethiopia
A “catastrophic” combination of drought and communities’ declining resilience has left an estimated 2.3 million people facing severe acute food insecurity – up from an estimate of 1.7 million people a month ago.
Communities across southern Africa have been affected by drought since late 2...018.
This year, large parts of southern and western Zambia received their lowest seasonal rainfall totals since at least 1981, the base year from which normal rainfall is benchmarked. At the same time, northern and eastern parts of the country were affected by flash floods and waterlogging, resulting in poor harvests.
more
Kyiv, Ukraine 22-24 November 2010
Meeting Report
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
HIV patient monitoring and case surveillance
Vision 2030
Accessed: 17.11.2019
Recommended actions at international and national levels
It's time to deliver differently.
Accessed: 13.11.2019
The primary role of Benin’s Department of Pharmacy and Medicines (DPMED) is to develop and apply the national pharmaceutical policy. The main objective of this policy is to ensure the availability and accessibility of quality medicines for the population. To fulfill its mandate, DPMED aims to stre...ngthen its regulatory capacity, including the issuance of licenses to pharmaceutical establishments and the registration of pharmaceutical products. Benin’s current registration system shares core concerns that are common to most developing countries, notably the capacity to evaluate and monitor the security, efficacy, and quality of medicines and other health products. It is currently characterized by 1) poor or inadequate traceability of records or regulations (example: a product’s marketing authorization [MA] is often hard to find); 2) lack of evidence used in the regulatory decision-making process (reasons behind special import authorization, i.e., products without valid MAs); 3) inconsistent and unsecured archiving system; 4) limited human resources; and 5) an inefficient information management system
more